Confidence in Concept 2012 - University of Sheffield
Lead Research Organisation:
University of Sheffield
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Rahman A
(2019)
Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.
in eLife
Robertson A
(2014)
A Zebrafish Compound Screen Reveals Modulation of Neutrophil Reverse Migration as an Anti-Inflammatory Mechanism
in Science Translational Medicine
Robertson AL
(2016)
Identification of benzopyrone as a common structural feature in compounds with anti-inflammatory activity in a zebrafish phenotypic screen.
in Disease models & mechanisms
Rothman A
(2018)
P567Pulmonary artery denervation for the treatment of pulmonary arterial hypertension: preliminary results of the TROPHY 1 Study
in European Heart Journal
Rothman A
(2019)
Pulmonary artery denervation using catheter-based ultrasonic energy.
in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Rothman AM
(2015)
Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension.
in Circulation. Cardiovascular interventions
Rothman AMK
(2020)
Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study.
in JACC. Cardiovascular interventions
Shewring JR
(2021)
Refining a correlative light electron microscopy workflow using luminescent metal complexes.
in Methods in cell biology
Stokes CA
(2016)
Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes.
in Mucosal immunology
Zhou L
(2015)
Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline.
in JACC. Cardiovascular interventions
| Description | CBMNet NIBB Proof of Concept |
| Amount | £42,500 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2018 |
| Description | Clinical Lectureship |
| Amount | £200,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 09/2019 |
| Description | Determining Novel SMURF1 Signalling Pathways and Precision Medicine Strategies in Patients with Pulmonary Arterial Hypertension |
| Amount | £460,409 (GBP) |
| Funding ID | 206632/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 02/2023 |
| Description | Developing a novel anti-OPG therapy |
| Amount | £5,424 (GBP) |
| Funding ID | MRC Proximity to Discovery - Knowledge Exchange Funding |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 03/2019 |
| Description | Developmental Pathway Funding Scheme |
| Amount | £2,401,085 (GBP) |
| Funding ID | MR/M015491/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 01/2018 |
| Description | Developmental Pathway Funding Scheme |
| Amount | £521,681 (GBP) |
| Funding ID | MR/L023040/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 02/2016 |
| Description | HC Roscoe Grant |
| Amount | £50,000 (GBP) |
| Organisation | British Medical Association (BMA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2015 |
| Description | PhD studentship |
| Amount | £21,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | Research Grant |
| Amount | £1,204,230 (GBP) |
| Funding ID | MR/M004864/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2019 |
| Description | Senior Basic Science Research Fellowship |
| Amount | £1,010,100 (GBP) |
| Funding ID | FS/13/48/30453 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2013 |
| End | 11/2018 |
| Description | Starter Grant |
| Amount | £30,000 (GBP) |
| Organisation | Academy of Medical Sciences (AMS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | Kymab |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Lead on a project developing Anti-OPG and TRAIL therapies for Pulmonary hypertension |
| Collaborator Contribution | Developed monoclonal antibodies and partner on successful DPFS application. |
| Impact | Partner on successful DPFS application. |
| Start Year | 2013 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | Medtronic |
| Country | United States |
| Sector | Private |
| PI Contribution | Lead and carry out a project on radiofrequency ablation for the treatment of pulmonary hypertension |
| Collaborator Contribution | In kind provision of cardiac stents |
| Impact | Presentation at TCT 2013 conference. Applications for further grants resulting in part from CiC funding are pending. |
| Start Year | 2013 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | National Institute for Health Research |
| Department | NIHR Devices for Dignity Healthcare Technology Co-Operative |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Lead on a project looking at detecting early onset of urinary tract infection in patients. |
| Collaborator Contribution | D4D's input adds a monetary contribution and expertise in target condition management and working with the NHS. D4D also provide market and intellectual property expertise. |
| Impact | Intended outputs are currently confidential. This is a multi-discplinary project involving clinicians, engineers, bioscientists and market expertise and product design. |
| Start Year | 2013 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | PhytoQuest Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Lead with developing small molecule channel modulators to treat polycystic kidney disease. |
| Collaborator Contribution | Provided a set of natural compounds |
| Impact | None |
| Start Year | 2013 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lead on a project to develop a new drug to inhibit viral-induced airway inflammation. |
| Collaborator Contribution | Input into new study ideas developing from CiC award. |
| Impact | Collaborative opportunities are still under discussion. |
| Start Year | 2013 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 1 of the Confidence in Concept Scheme |
| Organisation | University of Surrey |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lead project on development of a long-acting clotting factor to provide a prophylactic therapy for haemophiliac patients. |
| Collaborator Contribution | Identification of a new programme of work to further develop project. |
| Impact | Discussions are ongoing as to further outcomes. |
| Start Year | 2013 |
| Title | CLOTTING FACTOR |
| Description | The disclosure relates to long acting fusion polypeptides comprising Factor VIII [FVIII] and Factor IX [FIX] and their use in the treatment of blood clotting disorders. |
| IP Reference | WO2018037217 |
| Protection | Patent granted |
| Year Protection Granted | 2018 |
| Licensed | Commercial In Confidence |
| Impact | Commercial In Confidence |
| Title | Developing therapies for Pulmonary Hypertension |
| Description | The disclosure relates to agents that inhibit the activity of osteoprotegerin (OPG) and their use in the treatment of pulmonary hypertension. |
| IP Reference | US20140255404 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Other patent application: EP2773668 |
| Title | PULMONARY HYPERTENSION |
| Description | The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension. |
| IP Reference | WO2013064810 |
| Protection | Patent granted |
| Year Protection Granted | 2013 |
| Licensed | Commercial In Confidence |
| Impact | Commercial In Confidence |
| Company Name | PH Therapeutics Limited |
| Description | PH Therapeutics Ltd is a new business that intends to develop novel antibody therapies to treat the orphan disease Pulmonary Arterial Hypertension (PAH). The goal is to develop these new therapies to the clinic and to bring benefit to patients suffering from this rare and debilitating disease. |
| Year Established | 2013 |
| Impact | Through the work of Dr Allan Lawrie at the University of Sheffield, PH Therapeutics is developing novel antibody therapies that aim to reverse the progression of pulmonary arterial hypertension leading to improved treatments for patients. |
| Website | http://phtherapeutics.com/ |